• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Jun20
Inozyme Pharma Postpones Shareholders' Meeting Due to Acquisition
21:01
May19
FactSet Analysts Give Inozyme Pharma Hold Rating, Price Target of $6.86
11:47
Piper Sandler Downgrades Inozyme Pharma Inc to Neutral
03:18
UBS downgrades INOZYME PHARMA INC rating to neutral
03:14
May16
BioMarin Pharmaceuticals Acquires Inozyme Pharma
11:38
May15
Inozyme Pharma released FY2025 Q1 earnings on May 14 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4362 (forecast USD -0.3985)
03:00

Schedules & Filings

Schedules
Filings
May14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -28.04 M, EPS -0.4362

Mar10
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Net Income -27.07 M, EPS -0.4214

Nov5
Earning Release(EST)

FY2024 Q3 Earning Release (USD) Net Income -24.57 M, EPS -0.3882

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
TGL
19.600
+190.03%
+13.322
SMX
305.000
+116.31%
+164.000
WHLR
5.554
+71.41%
+2.314
GURE
7.450
+57.17%
+2.710
DBRG
14.470
+48.87%
+4.760
IRBT
4.285
+41.42%
+1.260
TORO
5.400
+30.75%
+1.270
LICN
3.830
+30.72%
+0.900
SPHL
4.350
+30.63%
+1.020
TDIC
0.3653
+30.09%
+0.085
View More